Heritable polymorphism predisposes to high BAALC expression in acute myeloid leukemia

Proceedings of the National Academy of Sciences of the United States of America

Volumn 109, Issue 17, 2012, Pages 6668-6673

  Eisfeld, Ann Kathrin ^a   Marcucci, Guido ^a   Liyanarachchi, Sandya ^a   Döhner, Konstanze ^b   Schwind, Sebastian ^a   Maharry, Kati ^a,c   Leffel, Benjamin ^a   Döhner, Hartmut ^b   Radmacher, Michael D ^a   Bloomfield, Clara D ^a   Tanner, Stephan M ^a   De La Chapelle, Albert ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b UNIVERSITY HOSPITAL ULM   (Germany)

^c MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TRANSCRIPTION FACTOR RUNX1;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ALLELE; ARTICLE; BRAIN AND ACUTE LEUKEMIA CYTOPLASMIC GENE; FEMALE; GENE; GENE EXPRESSION; GENETIC POLYMORPHISM; GENETIC TRANSCRIPTION; GENOTYPE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; AGED; ALLELES; BINDING SITES; CORE BINDING FACTOR ALPHA 2 SUBUNIT; FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; NEOPLASM PROTEINS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC;

EID: 84860204453     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1203756109     Document Type: Article

References (54)

1. Farag SS, et al. (2005) Outcome of induction and postremission therapy in younger adults with acute myeloid leukemia with normal karyotype: A cancer and leukemia group B study. J Clin Oncol 23:482-493. (Pubitemid 46224225)
2. Fernandez HF, et al. (2009) Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med 361:1249-1259.
3. Burnett AK, et al. (2010) Attempts to optimize induction and consolidation treatment in acute myeloid leukemia: Results of the MRC AML12 trial. J Clin Oncol 28: 586-595.
4. Fröhling S, et al. (2006) Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years: Results from AMLSG trial AML HD98-B. Blood 108:3280-3288.
5. Estey E (2007) Acute myeloid leukemia and myelodysplastic syndromes in older patients. J Clin Oncol 25:1908-1915.
6. Burnett AK, et al. (2011) The addition of arsenic trioxide to low-dose Ara-C in older patients with AML does not improve outcome. Leukemia 25:1122-1127.
7. Whitman SP, et al. (2001) Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: A cancer and leukemia group B study. Cancer Res 61: 7233-7239. (Pubitemid 32946520)
8. Thiede C, et al. (2002) Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: Association with FAB subtypes and identification of sub-groups with poor prognosis. Blood 99:4326-4335. (Pubitemid 34627197)
9. Fröhling S, et al. (2004) CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: Prognostic relevance and analysis of cooperating mutations. J Clin Oncol 22:624-633. (Pubitemid 41095065)
10. Falini B, et al. (2005) Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med 352:254-266. (Pubitemid 40110814)
11. Schnittger S, et al. (2005) Nucleophosmin gene mutations are predictors of favorable prognosis inacute myelogenous leukemia with a normal karyotype. Blood 106:3733-3739. (Pubitemid 41739006)
12. Döhner K, et al. (2005) Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: Interaction with other gene mutations. Blood 106:3740-3746. (Pubitemid 41739007)
13. Farag SS, et al. (2006) Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: Results from Cancer and Leukemia Group B 8461. Blood 108:63-73. (Pubitemid 43996625)
14. Heuser M, et al. (2006) High meningioma 1 (MN1) expression as a predictor for poor outcome in acute myeloid leukemia with normal cytogenetics. Blood 108:3898-3905. (Pubitemid 44864574)
15. Tonks A, et al. (2007) CD200 as a prognostic factor in acute myeloid leukaemia. Leukemia 21:566-568.
16. Mrózek K, Marcucci G, Paschka P, Whitman SP, Bloomfield CD (2007) Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: Are we ready for a prognostically prioritized molecular classification? Blood 109:431-448. (Pubitemid 46105936)
17. Marcucci G, et al. (2005) Overexpression of the ETS-related gene, ERG, predicts a worse outcome in acute myeloid leukemia with normal karyotype: A Cancer and Leukemia Group B study. J Clin Oncol 23:9234-9242.
18. Marcucci G, et al.; Cancer and Leukemia Group B Study (2007) High expression levels of the ETS-related gene, ERG, predict adverse outcome and improve molecular risk- based classification of cytogenetically normal acute myeloid leukemia: A Cancer and Leukemia Group B study. J Clin Oncol 25:3337-3343. (Pubitemid 47325620)
19. Marcucci G, et al. (2008) Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: A Cancer and Leukemia Group B study. J Clin Oncol 26:5078-5087.
20. Marcucci G, et al. (2010) IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: A Cancer and Leukemia Group B study. J Clin Oncol 28:2348-2355.
21. Paschka P, et al. (2008) Wilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: A Cancer and Leukemia Group B study. J Clin Oncol 26:4595-4602.
22. Paschka P, et al. (2010) IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication. J Clin Oncol 28:3636-3643.
23. Langer C, et al. (2009) Prognostic importance of MN1 transcript levels, and biologic insights from MN1-associated gene and microRNA expression signatures in cytogenetically normal acute myeloid leukemia: A Cancer and Leukemia Group B study. J Clin Oncol 27:3198-3204.
24. Metzeler KH, et al. (2009) ERG expression is an independent prognostic factor and allows refined risk stratification in cytogenetically normal acute myeloid leukemia: A comprehensive analysis of ERG, MN1, and BAALC transcript levels using oligonucleotide microarrays. J Clin Oncol 27:5031-5038.
25. Metzeler KH, et al. (2011) TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: A Cancer and Leukemia Group B study. J Clin Oncol 29:1373-1381.
26. Becker H, et al. (2010) Mutations of the Wilms tumor 1 gene (WT1) in older patients with primary cytogenetically normal acute myeloid leukemia: A Cancer and Leukemia Group B study. Blood 116:788-792.
27. Becker H, et al. (2010) Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: A Cancer and Leukemia Group B study. J Clin Oncol 28:596-604.
28. Schwind S, et al. (2011) Low expression of MN1 associates with better treatment response in older patients with de novo cytogenetically normal acute myeloid leukemia. Blood 118:4188-4198.
29. Gaidzik VI, et al. (2011) RUNX1 mutations in acute myeloid leukemia: Results from a comprehensive genetic and clinical analysis from the AML study group. J Clin Oncol 29:1364-1372.
30. Ley TJ, et al. (2010) DNMT3A mutations in acute myeloid leukemia. N Engl J Med 363: 2424-2433.
31. Kindler T, Lipka DB, Fischer T (2010) FLT3 as a therapeutic target in AML: Still challenging after all these years. Blood 116:5089-5102.
32. Tanner SM, et al. (2001) BAALC, the human member of a novel mammalian neuro-ectoderm gene lineage, is implicated in hematopoiesis and acute leukemia. Proc Natl Acad Sci USA 98:13901-13906. (Pubitemid 33115996)
33. Baldus CD, et al. (2003) BAALC expression predicts clinical outcome of de novo acute myeloid leukemia patients with normal cytogenetics: A Cancer and Leukemia Group B study. Blood 102:1613-1618. (Pubitemid 37022550)
34. Bienz M, et al. (2005) Risk assessment in patients with acute myeloid leukemia and a normal karyotype. Clin Cancer Res 11:1416-1424. (Pubitemid 40315221)
35. Santamaría C, et al. (2010) BAALC is an important predictor of refractoriness to chemotherapy and poor survival in intermediate-risk acute myeloid leukemia (AML). Ann Hematol 89:453-458.
36. Eid MA, et al. (2010) BAALC and ERG expression in acute myeloid leukemia with normal karyotype: Impact on prognosis. Int J Lab Hematol 32:197-205.
37. Schwind S, et al. (2010) BAALC and ERG expression levels are associated with outcome and distinct gene and microRNA expression profiles in older patients with de novo cytogenetically normal acute myeloid leukemia: A Cancer and Leukemia Group B study. Blood 116:5660-5669.
38. Baldus CD, et al. (2007) Low ERG and BAALC expression identifies a new subgroup of adult acute T-lymphoblastic leukemia with a highly favorable outcome. J Clin Oncol 25:3739-3745. (Pubitemid 47376607)
39. Kühnl A, et al. (2010) High BAALC expression predicts chemoresistance in adult B-precursor acute lymphoblastic leukemia. Blood 115:3737-3744.
40. Schrama D, et al. (2008) BRAFV600E mutations in malignant melanoma are associated with increased expressions of BAALC. J Carcinog 7:1.
41. Agaram NP, et al. (2008) Molecular characterization of pediatric gastrointestinal stromal tumors. Clin Cancer Res 14:3204-3215.
42. Heuser M, et al. (2011) Functional role of BAALC in leukemogenesis. Leukemia 26: 532-536.
43. Morley M, et al. (2004) Genetic analysis of genome-wide variation in human gene expression. Nature 430:743-747.
44. Cheung VG, et al. (2005) Mapping determinants of human gene expression by regional and genome-wide association. Nature 437:1365-1369. (Pubitemid 41568683)
45. Göring HH, et al. (2007) Discovery of expression QTLs using large-scale transcriptional profiling in human lymphocytes. Nat Genet 39:1208-1216. (Pubitemid 47482685)
46. Stephens M, Donnelly P (2003) A comparison of Bayesian methods for haplotype reconstruction from population genotype data. Am J Hum Genet 73:1162-1169. (Pubitemid 37414228)
47. Friedman AD (2009) Cell cycle and developmental control of hematopoiesis by Runx1. J Cell Physiol 219:520-524.
48. Levine RL, et al. (2005) Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7:387-397. (Pubitemid 40544655)
49. Jones AV, et al. (2009) JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms. Nat Genet 41:446-449.
50. Kilpivaara O, et al. (2009) A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms. Nat Genet 41:455-459.
51. Olcaydu D, et al. (2009) A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms. Nat Genet 41:450-454.
52. Hermouet S, Vilaine M (2011) The JAK2 46/1 haplotype: A marker of inappropriate myelomonocytic response to cytokine stimulation, leading to increased risk of inflammation, myeloid neoplasm, and impaired defense against infection? Haematologica 96:1575-1579.
53. Byrd JC, et al.; Cancer and Leukemia Group B 8461 (2002) Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: Results from Cancer and Leukemia Group B (CALGB 8461). Blood 100:4325-4336.
54. Mrózek K, et al. (2008) Central review of cytogenetics is necessary for cooperative group correlative and clinical studies of adult acute leukemia: The Cancer and Leukemia Group B experience. Int J Oncol 33:239-244.